Last reviewed · How we verify
placebo for remdesivir
placebo for remdesivir is a Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Control arm in remdesivir clinical trials (likely COVID-19 or viral respiratory infection).
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in remdesivir clinical trials (likely COVID-19 or viral respiratory infection).
At a glance
| Generic name | placebo for remdesivir |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-based response). In this context, the placebo serves as the control arm in a Phase 3 trial comparing remdesivir efficacy.
Approved indications
- Control arm in remdesivir clinical trials (likely COVID-19 or viral respiratory infection)
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised (PHASE3)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (PHASE3)
- Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) (PHASE3)
- A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects (PHASE1)
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial (PHASE4)
- Trial of Treatments for COVID-19 in Hospitalized Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo for remdesivir CI brief — competitive landscape report
- placebo for remdesivir updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about placebo for remdesivir
What is placebo for remdesivir?
How does placebo for remdesivir work?
What is placebo for remdesivir used for?
Who makes placebo for remdesivir?
What development phase is placebo for remdesivir in?
Related
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Control arm in remdesivir clinical trials (likely COVID-19 or viral respiratory infection)
- Compare: placebo for remdesivir vs similar drugs
- Pricing: placebo for remdesivir cost, discount & access